SynthesisBMJ open2021
Coenzyme Q10 supplementation for prophylaxis in adult patients with migraine-a meta-analysis.
Synthesis in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Oral preventive medications for migraine in adults aged 18-65: a network meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Coenzyme Q10 as an adjunctive strategy to reduce paclitaxel-induced toxicities in breast cancer: a randomized controlled trial.BMC pharmacology & toxicology · 2026Trial
- A Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Effects of Commercially Available Ubiquinone, Ubiquinol, and Geranylgeraniol Dietary Supplements on Plasma CoQ10 Concentrations.Journal of nutrition and metabolism · 2026Article
- Effect of coenzyme Q10 on pain prevention after thoracoscopic surgery: study protocol.Pain management · 2025Article
- Mitochondrial Impairment in Healthy Controls With Recent Headache and Multiple Symptoms.Cureus · 2025Article
- Coenzyme Q10 microemulsion ion-activated gel: a promising ophthalmic delivery system for enhanced corneal protection and sustained release.BMC pharmacology & toxicology · 2025Article
- Nutraceuticals and Headache 2024: Riboflavin, Coenzyme Q10, Feverfew, Magnesium, Melatonin, and Butterbur.Current pain and headache reports · 2025Review
- Bridging Gaps in Migraine Management: A Comprehensive Review of Conventional Treatments, Natural Supplements, Complementary Therapies, and Lifestyle Modifications.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Sexual Dimorphism in Migraine. Focus on Mitochondria.Current pain and headache reports · 2025Review
- Energy metabolism disorders in migraine: triggers, pathways, and therapeutic repurposing.Frontiers in neurology · 2025Review
- Investigating GLP-1 Injections: Potential Mitochondrial Dysfunction in Non-Diabetic Patients Presenting with Migraines and Hypoglycemia: A Case Report.Integrative medicine (Encinitas, Calif.) · 2024Article
- Eyebrow bleeding as a rare migraine symptom: a case report.Annals of medicine and surgery (2012) · 2024Article
- Oxidative Stress and Migraine.Molecular neurobiology · 2024Review
- Effects of β-sitosterol on anxiety in migraine-induced rats: The role of oxidative/nitrosative stress and mitochondrial function.CNS neuroscience & therapeutics · 2024Article
- Bioenergetic impairment in Gulf War illness assessed viaScientific reports · 2024Article
- Conservative Management of Acute Sports-Related Concussions: A Narrative Review.Healthcare (Basel, Switzerland) · 2024Review
- Prospects of Intravenous Coenzyme Q10 Administration in Emergency Ischemic Conditions.Life (Basel, Switzerland) · 2024Review
- Evidence-Based Opinions from Multidisciplinary Experts on Use of Naturopathic Herbal Remedies in Pain Management.Journal of pain research · 2024Review
- Practical supplements for prevention and management of migraine attacks: a narrative review.Frontiers in nutrition · 2024Review
- Targeting Glutamate Neurotoxicity through Dietary Manipulation: Potential Treatment for Migraine.Nutrients · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the effects of coenzyme Q10 (CoQ10) for reduction in the severity, frequency of migraine attacks and duration of headache in adult patients with migraine.
designSystematic review and meta-analysis. DATA SOURCES: Cochrane Central Register of Controlled Trials, CENTRAL, MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL) and Psychological Information Database (PsycINFO) from inception till December 2019. STUDY SELECTION: All randomised control trials comparing CoQ10 with placebo or used as an adjunct treatment included in this meta-analysis. Cross-over designs and controlled clinical trials were excluded. DATA SYNTHESIS: Heterogeneity at face value by comparing populations, settings, interventions and outcomes were measured and statistical heterogeneity was assessed by means of the I
resultsSix studies with a total of 371 participants were included in the meta-analysis. There is no statistically significant reduction in severity of migraine headache with CoQ10 supplementation. CoQ10 supplementation reduced the duration of headache attacks compared with the control group (MD: -0.19; 95% CI: -0.27 to -0.11; random effects; I
conclusionCoQ10 appears to have beneficial effects in reducing duration and frequency of migraine attack. PROSPERO REGISTRATION NUMBER: CRD42019126127.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.